Background. To investigate clinical variables such as gestational age, sex, weight, the therapeutic regimens used and mechanical ventilation that might affect morphine requirements and plasma concentrations of morphine and its metabolites.
Morphine is the most frequently used agent for postoperative analgesia in neonates, infants and children. 1±5 Therapeutic plasma concentrations of morphine depend on factors such as route of administration, total body clearance and volume of distribution. These are affected by the age, hepatic function, renal function and clinical condition. 6±9 As a result of these factors, studies of morphine pharmacokinetics report a noticeable variability between patients. 10 While preterm neonates are regarded as a separate group with regard to serum half-life and morphine clearance, the distinction between term newborns and older infants is less clearly de®ned. 10 In addition, the pharmacodynamics of morphine may change rapidly during infancy, being in¯u-enced by sex, 11 the maturation of opioid receptors, 12±14 earlier experiences of pain, 15 as well as social and cultural factors. 16 Despite the reported variability, most previous studies have investigated the effects of morphine only in 4±20 patients within the different age groups, 10 thus precluding their ability to examine the effects of underlying clinical and demographic factors.
We designed a prospective study including larger numbers of patients in each age group, enabling us to elucidate the impact of various clinical and demographic variables on both morphine requirements and morphine pharmacokinetics. We have recently reported the effects of morphine administration on hormonal and metabolic stress responses following major surgery in the same patient population. 17 
Methods
After approval from the Medical Ethics Committee for the Erasmus MC, Rotterdam, written consent was obtained from all parents. We included 204 children aged 0±3 yr admitted to the paediatric surgical intensive care unit following non-cardiac thoracic and abdominal surgery. Patients were excluded if they had received morphine <6 h before surgery, or suffered from hepatic, renal or neurological disorders. Patients were strati®ed into four age groups: group I 0±4 weeks, group II 4±26 weeks, group III 26±52 weeks, group IV 1±3 yr. They were randomly assigned to receive either i.v. continuous morphine (CM) or intermittent morphine (IM). The pharmacist prepared all study drugs and strata-speci®c schedules for randomization. For each age group, the boxes containing the study drugs were numbered consecutively and used in sequence. Each patient received a study number consisting of a number of the age group (I±IV) and a sequence number (1±68).
Anaesthetic management was standardized in all patients. Anaesthesia was induced with i.v. thiopental 3±5 mg kg ±1 or, when i.v. induction was impossible, by inhalation of halothane in oxygen (<5% of patients). After the insertion of an i.v. line, the anaesthetic procedure was similar for all patients. Fentanyl 5 mg kg ±1 was given before orotracheal intubation, which was facilitated with atracurium 0.5±1 mg kg ±1 or succinylcholine 2 mg kg ±1 . Ventilation was controlled and anaesthesia was maintained with iso¯urane 0.5 minimum alveolar concentration in nitrous oxide 60% in oxygen or air in oxygen. Perioperative¯uids were standardized to maintain a glucose infusion rate of 4±6 mg kg ±1 min ±1 . Body temperature was kept within normal ranges. A peripheral artery was cannulated and the measured mean arterial pressure (MAP) and heart rate (HR) data served as preoperative baseline data. Patients received a second dose of fentanyl 5 mg kg ±1 before surgical incision and additional doses of fentanyl 2 mg kg ±1 when HR and/or MAP were 15% above the baseline values. At the end of surgery, the neuromuscular block was antagonized and the tracheal tube removed. Mechanical ventilation was continued in patients who required ventilatory assistance after surgery.
The anaesthetist and the surgeon then jointly computed the surgical stress score (SSS). 18 This measure takes into account seven items: amount of blood loss, site of surgery, amount of super®cial trauma, extent of visceral trauma, duration of surgery, associated stress factors (hypothermia, localized or generalized infection, and prematurity) and cardiac surgery. The total scores in this study (excluding cardiac surgery and prematurity <35 weeks) could range from 3 to 24.
Directly after surgery, all patients received an i.v. loading dose of morphine hydrochloride 100 mg kg ±1 in 2 min. For children in the CM group this was followed by a morphine infusion 10 mg kg ±1 h ±1 , combined with 3-hourly i.v. placebo (saline) boluses. Children in the IM group received 3-hourly i.v. morphine 30 mg kg
±1
, combined with a continuous placebo infusion (saline). The amount of glucose and the volume of¯uid was the same in both treatment groups. The clinical staff were blinded to the study group allocation until data collection was complete. The continuous infusion was started within 30 min after the loading dose; the ®rst intermittent bolus (morphine or placebo) was given 3 h after surgery.
Pain was assessed by nurses trained in the use of the behavioural part of the COMFORT scale (CS), 19 20 the total score of which can range from 6 to 30, and a 0±10 visual analogue scale (VAS). The modi®ed CS counts six behavioural items: alertness, calmness, respiratory response (for mechanically ventilated children) or crying (for nonventilated children), movement, muscle tone and facial tension. 20 VAS scores were taken after the 2-min observation periods needed for the CS. Additional analgesia was given when there were signs of pain, indicated by VAS score b4. During the ®rst hour after surgery, one-third of the loading dose of morphine could be repeated every 15 min, and thereafter morphine 5 mg kg ±1 every 10 min if required. Nursing interventions included pain assessment, blood sampling and administration of intermittent bolus (placebo or morphine) medication, and then nursing as needed. No other analgesic or sedative drugs were used. Arterial blood samples were taken after induction of anaesthesia (baseline), at the end of surgery, and at 6, 12, and 24 h after surgery for measurement of blood gas values and plasma concentrations of morphine, morphine-3-glucuronide (M3G) and morphine-6-glucuronide (M6G). Respiratory depression was de®ned by the presence of apnoea or arterial Pa CO 2 b7.3 kPa in spontaneously breathing patients. 21 Blood samples were taken at time points corresponding with trough plasma morphine concentrations in the IM group.
Morphine and metabolite assay
The blood samples (1.4 ml) were centrifuged at 3000 rpm for 10 min and the serum was stored at ±20°C until analysis. Serum aliquots (0.6 ml) were extracted with the Baker-10 extraction system (Baker Chemicals, Deventer, the Netherlands) ®tted with 1-ml disposable cyclohexyl cartridges (Baker, Chemicals, Deventer, the Netherlands). The extraction column was conditioned with two column volumes methanol, two column volumes water and diammonium sulphate 1 ml 500 mM, pH 9.3. The serum (0.6 ml) was diluted with diammonium sulphate 0.6 ml 500 mM, pH 9.3 before being introduced into the extraction column. It was washed with diammonium sulphate 2 ml 50 mM, pH 9.3, after which it was allowed to dry for 15 s. The elution was carried out with KH 2 PO 4 buffer 0.5 ml 0.01 M, pH 2.1 containing acetonitrile 11%. From this elute 50 ml was injected onto the analytical column.
The HPLC system comprised a Spectro¯ow 400 solvent delivery system (Kratos, Rotterdam, the Netherlands) equipped with a degasser (Separations, HI-Ambacht, the Netherlands), a Marathon auto sampler (Separations, HIAmbacht, the Netherlands), a Spectro¯ow 773 UV detector at l=210 nm (Separations, HI-Ambacht, the Netherlands), in sequence with an ESA electrochemical detector (ESA, Kratos, Rotterdam, the Netherlands) equipped with an analytical cell (Model 5010). All compounds leave the UV detector chemically intact and so the electrochemically active components can be oxidized in the electrochemical cell. This type of electrochemical cell contains two separate analytical cells, which makes it possible to create a small window of applied potential. The detector 2 potential was set at 0.4 V, while the detector 1 potential was 0.3 V. This minimizes interfering peaks because only compounds with an oxidation potential of 0.3±0.4 V are recorded. Chromatographic separations were achieved using a CpSper C8 column (250Q4.6 mm) (Chrompack, Bergen op Zoom, the Netherlands). The mobile phase was KH 2 PO 4 buffer 0.01 M, pH 2.1 containing acetonitrile 11% and heptane sulphonic acid 0.4 g litre ±1 . For the measurement of M3G, M6G and morphine, calibration samples contained all three compounds. In serum, all three calibration graphs (six data points) were linear in the concentration ranges 25±580 ng ml ±1 (r=0.9992) for M3G, 5±100 ng ml ±1 (r=0.9982) for M6G and 5±90 ng ml ±1 (r=0.9963) for morphine. The quanti®-cation limit was 5 ng ml ±1 for morphine and M6G and 25 ng ml ±1 for M3G. However, in individual samples, the chromatogram allowed for a lower threshold. As we used median values in this study, these are not affected by the values under the detection limit. In this concentration range, the intra-and inter-day precision was less than 10% for all compounds and the accuracy was about 5% (Table 1) . 22 23 Standardized automated laboratory analysers were used to measure plasma concentrations of bilirubin and creatinine. Table 1 Intra-day (n=5) and inter-day (n=8) coef®cients of variation (% CV) of spiked morphine and its metabolites in human serum in vitro. Accuracy is the ability to measure the quantity of the compound being determined. Precision: a method is precise if it yields the same results for a series of replicate determinations 
Statistical analysis
Relations between age and plasma concentrations of morphine, M3G and M6G were investigated using ANOVA.
We applied multiple regression analysis to determine the effects of the gestational age, sex, birth weight, study weight, preoperative and postoperative mechanical ventilation, preoperative plasma concentrations of creatinine and total bilirubin, SSS, location of surgery, morphine treatment and a history of previous surgery, in addition to age on morphine requirements and plasma concentrations of morphine and its metabolites. In all analyses, the morphine and metabolite plasma concentrations were transformed logarithmically in order to approximate normal distribution. Relations between the various factors and the need (yes/no) for extra morphine were assessed by logistic regression analysis.
All 204 patients were included in an intention-to-treat analysis. Seven had to be excluded from morphine data analysis (4 in CM, 3 in IM): ®ve had detectable morphine plasma concentrations at baseline as a result of previous morphine administration (congenital diaphragmatic hernia, n=4; meconium peritonitis, n=1), one patient died within 3 h after surgery (vessel loop and therapy-resistant pulmonary hypertension), and another patient required neuromuscular blockade after surgery (hemi-hepatectomy). Logistic and laboratory problems resulted in missing data for several of the 197 included patients. Spearman's rho was used for correlation coef®cients and the other statistical tests used are given in the text. To control the a-error for the multiple statistical tests performed, the level of signi®cance was set at P=0.01, instead of the conventional P=0.05. The power analysis for the comparative randomized trial was given in the original article. 17 In the present paper the effects of age and various other factors are investigated with respect to morphine requirements and plasma concentrations. With a study group of 200 infants, correlations as small as r=0.25 are detectable (a=0.01) with a power greater than 80%. Table 2 gives the clinical and surgical characteristics of the 197 enrolled patients, strati®ed by age group and randomized treatment group (97 in the CM group and 100 in the IM group).
Results
Patient characteristics and clinical variables within the four age groups were similar in the two randomized groups. Although the surgical procedures varied, the age and treatment groups had similar SSS. Patient data and details of surgery in the four ages groups (I 0±4 weeks, II b4±26 weeks, III b26±52 weeks, IV b1±3 yr). Data are mean (SD) unless stated otherwise (3) 38 (2) 37 (4) 37 (5) 37 (5) 37 (5) 38 (2) (22) 47 (25) 26 (18) 23 (14) 31 (36) 54 (45) 28 (36) 27 (16) Plasma total bilirubin (mmol litre ±1 )
91 (67) 108 (56) 23 (39) 35 (55) 15 (31) 7 (3) 6 (2) 7 (3) Plasma bilirubin glucuronide concentration (mmol litre ±1 ) 6 (4) 9 (8) 14 (26) 23 (42) 12 (32) 2 (1) 3 (1) 3 (1) Mechanical ventilation before surgery (n) CM=continuous morphine, IM=intermittent morphine.
Morphine therapy in postoperative infants
Overall, there were signi®cant differences in the use of extra morphine between the age groups (P<0.001), but not between the treatment groups. Table 3 shows the need for extra morphine and the total requirement for morphine (excluding the loading dose) in the four age groups. Only 38% of neonates (group I) required additional morphine, a signi®cantly lower percentage than in all older age groups. Signi®cantly more infants aged 4±26 weeks required additional morphine than the children aged 1±3 yr.
Multiple logistic regression analysis of all variables showed that age group, plasma concentrations of total bilirubin and the SSS were the most important factors affecting the need for additional morphine. The percentage of patients needing extra morphine was signi®cantly higher in group II than in group I (91% vs 38%, P<0.001). In all age groups, increases in plasma bilirubin concentrations reduced the need for extra morphine (P=0.01) whereas a higher SSS increased the need for extra morphine (P=0.007).
During the ®rst hour after the loading dose, the need for additional morphine was only related to age. A signi®cantly higher percentage of patients in group II than in group I (P=0.01) needed extra morphine in this period. There was no consistency in the need for extra morphine during the ®rst hour after surgery and/or between the other time periods (1±6, b6±12, b12±18 and b18±24 h after surgery). Figure 1 shows the percentage of patients needing additional morphine during each of these periods.
The age of the child and type of morphine administration signi®cantly affected the morphine dosage (kg ±1 day ±1 ) required. However, inherent to the protocol design, the dosage in the CM group was always 30 mg kg ±1 higher than in the IM group. Disregarding this in the CM group, there was no difference between the groups. Group I needed signi®cantly less morphine than the other age groups (ANOVA, P<0.001) ( Table 3) .
Analysis of morphine plasma concentrations 6 h after surgery revealed a signi®cant difference between age groups depending on the type of morphine administration. Therefore, the effect of age groups was evaluated within the treatment groups separately. Plasma concentrations at 12 and 24 h after surgery were no longer dependent on type of treatment. Table 4 gives the plasma concentrations of morphine and its metabolites M3G and M6G, and the differences between age and treatment groups at 6, 12 and 24 h after surgery. Plasma concentrations were signi®cantly higher in group I than in the other groups, and in group II vs group IV (Table 4) . ANOVA showed that morphine plasma concentrations were signi®cantly affected by the total morphine dose administered (P<0.001). Plasma morphine concentrations in the CM neonatal group (at 12 and 24 h after surgery) were signi®cantly correlated with plasma creatinine concentrations (r=0.5, P=0.01; r=0.4, P=0.04, respectively), and with plasma bilirubin concentrations (both r=0.6, P=0.001).
Dif®culties in detection of M3G plasma concentrations in the neonatal group (interfering spikes) resulted in many missing values for M3G in this group (n=32). ANOVA of M3G and M6G plasma concentrations revealed that the age group and the administered dosage of morphine signi®-cantly affected these plasma concentrations (both P<0.001). Although plasma concentrations of M3G and M6G were higher after CM than after IM, this difference was only signi®cant for M3G at 6 h after surgery. M3G and M6G plasma concentrations were signi®cantly higher in group I than in the other groups, and in group II vs group IV at 12 and 24 h after surgery (all P<0.001) ( Table 4 ). M6G plasma concentrations correlated signi®cantly with plasma creatinine only in the neonates, and only in CM at 12 and 24 h after surgery (r=0.5, P=0.01 and r=0.5, P=0.002, respectively). No such correlation was found for M3G. Figure 2 shows the median plasma concentrations of morphine, M3G and M6G in the four age groups for CM and IM at 6, 12 and 24 h after surgery. Table 5 gives the ratios of morphine and its metabolites at 24 h after surgery, and the signi®cant differences between age groups. The M6G/M ratio showed signi®cant differences between age groups but not between the different treatments. The M6G/M ratio was lower in group I than in all other groups. Neither age nor treatment at any time point had any signi®cant effect on the M6G/M3G ratio (Table 5) . Eleven spontaneous breathing patients (8 in the IM group, 3 in the CM group) developed postoperative respiratory insuf®ciency; seven of them required intubation (5 in the IM group, 2 in the CM group). Details of age, treatment, surgical procedure, requirement of morphine and complications are given in Table 6 . Table 7 gives an overview of studies reporting requirements and plasma concentrations of morphine after noncardiac surgery, including the present data.
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Discussion
In this clinical study we investigated (i) the effects of various variables on the morphine dose required in infants, and (ii) the age-related changes in morphine and metabolite concentration. Age was the most important factor differentiating dose requirements between neonates and infants older than 4 weeks. In a recent meta-analysis, a continuous infusion rate of 7 mg kg ±1 h ±1 was calculated for term neonates, assuming a desired steady-state plasma concentration of 15 ng ml ±1 for all ages. 27 Neonates in our current study received higher infusion rates and the concentrations are proportionally similar. Because more than 60% of the neonates had adequate analgesia with the minimal dose of 10 mg kg ±1 h ±1 (median concentration 22 ng ml ±1 ), it is likely that a lower dose of morphine would have suf®ced for the neonates. Signi®cantly more morphine was used in the older children, with requirements ranging from (median) 10.9 to 12.3 mg kg ±1 h ±1 . Even with the additional morphine, the required dose was lower than the recommended dosage of 20 mg kg ±1 h ±1 . 27±31 Remarkably, of the age groups older than 4 weeks, children aged 1±3 yr needed the lowest dosage of morphine (NS). They also had the lowest plasma concentrations of morphine, which suggests that their clearance was the highest.
Because concentration is directly proportional to dose, we need to determine clearance in order to predict dose. The wide range of neonatal plasma concentrations reported in the literature was as expected, given the variability in interindividual clearance (Table 7) . In our study, plasma concentrations of morphine in neonates (n=63) provided adequate analgesia between 15.4 (trough) and 22 ng ml ±1 , and, in infants older than 4 weeks (n=134), between 1.0 and 7.5 ng ml ±1 . These low plasma concentrations of morphine apparently produced effective analgesia, as evidenced by the low postoperative CS and VAS scores. It seems that plasma concentrations as high as 15 ng ml ±1 are not necessary for adequate postoperative analgesia in infants >4 weeks of age. Although at the time of surgery all patients had been without morphine therapy for more than 6 h, plasma morphine was still detectable in ®ve neonates. This indicates that clearance in this age group is low (approxi- Table 4 Plasma concentrations (ng ml ±1 ) of morphine, morphine-3-glucuronide (M3G) and morphine-6-glucuronide (M6G) at 6, 12 and 24 h after surgery, according to age (group I 0±4 weeks, group II b4±26 weeks, group III b26±52 weeks, group IV b1±3 yr) and treatment group. Data are median (interquartile range). Morphine therapy in postoperative infants mately 9 ml kg ±1 min ±1 ). 9 Plasma morphine concentrations were signi®cantly dependent on age, bearing in mind that patients with renal impairment were not included. Differences between treatment groups were only found at 6 h after surgery. Extra morphine dosages, given by nurses on the basis of observational pain scores, resulted in similar plasma concentrations in CM and IM from 12 h after surgery. In the CM group, median concentrations decreased from 7.4 to 6.4 to 4.8 ng ml ±1 with increasing age in groups II, III and IV. These data are consistent with an increase in plasma clearance over the age range investigated.
Plasma concentrations of morphine that should produce effective analgesia in neonates and older children have been reported to range from 3.8 (SD 2.5) to 125 (9) ng ml ±1 .
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This wide range results from the various pain stimuli or sedation end-points, differences in pain perception and pain assessment, and variations in the children's clinical state (severe illness, mechanical ventilation, needing sedation or analgesia, tolerance, etc.). As reported earlier, the relation between morphine requirement and plasma concentrations is also dependent on the type of surgery, which leads to different results after cardiac or non-cardiac surgery. 6 34 Morphine is mainly metabolized in the liver into M3G and M6G by uridine diphosphate glucuronyltransferase (UDG2B7). The kidneys excrete these metabolites, as well as a portion of the unchanged morphine. Developmental maturation, associated with increasing renal clearance and decreasing drug half-life, starts in the early neonatal period and goes on for 2 yr. Using the three-quarters power model, adult levels of clearance were reached at an earlier age (2±6 months). 35 High morphine plasma concentrations and low M3G/M and M6G/M ratios, as were found in the neonates, might indicate a low glucuronidation capability. However, from 12 h after surgery, the highest plasma concentrations of M3G and M6G were found in the neonates, showing that they were able to glucuronidate morphine. Nevertheless, hepatic induction of these enzyme systems cannot be ruled out. The high plasma concentrations of morphine metabolites in the neonates were the result of low renal clearance, which was con®rmed by the signi®cant correlation between serum creatinine and M6G in this age group. The decreased clearance of morphine explains its increased analgesic effect in neonates, contributed to by the active metabolite M6G. While the M3G/M and M6G/M ratios increased with age, indicating improved morphine metabolism, the M3G and M6G plasma concentrations decreased with age, indicating improved renal excretion, as reported in other studies as well. 7 34 36 37 In the present study, plasma concentrations of morphine and morphine metabolites were not only signi®cantly different between neonates (group I) and the older children (groups II, III and IV), but also between infants aged 4±26 weeks (group II, median age 3 months) and 1±3 yr (group IV, median age 20 months). The major changes in morphine metabolism and elimination apparently take place in the ®rst 3 months after birth, and only minor differences in morphine clearance are found after that age. The development of the glucuronidation capability and the renal function might have resulted in lower plasma concentrations of morphine in the older children. Clinical effects, however, may be more dependent on the concentrations in brain tissue, receptor characteristics 14 and other factors. Reported correlations between metabolite/morphine ratios and gestational age or birth weight are controversial. M3G/M and M6G/M ratios increased with increasing birth weight 37 38 and gestational age 38 (glucuronidation capability increases), which was not found by Barrett and colleagues. 39 The disparity in plasma morphine glucuronide ratios between the different studies could be a result of the varying number of patients in the individual studies, differences in gestational age and study age, in detection limits of metabolites, and in the duration of morphine infusions and the time of sampling. Because M3G and M6G have long half-lives in neonates 39 (impaired renal function), it is suggestive that in neonates the M6G/M and M3G/M ratios are increasing with increased periods of morphine infusion.
In a review examining the effects of age, renal impairment and route of administration on morphine metabolism, Faura and colleagues 7 reported a consistently high correlation between M6G and M3G, with a ratio of about 15% in neonates and children, as in adults. Across all studies, the range of the ratios of metabolites to morphine was wide. However, there was almost complete overlap between children (>1 month) and adults, but neonates (<1 month) had discernibly lower ratios for both metabolites. Although Table 5 Ratios of metabolites (morphine-3-glucuronide, M3G; morphine-6-glucuronide, M6G) and morphine (M) 24 h after surgery (group I 0±4 weeks, group II b4±26 weeks, group III b26±52 weeks, group IV b1±3 yr). *P<0.003 group I vs groups III and IV; P=0.03 group I vs group II (CM and IM) (ANOVA). Values are median (interquartile range) Morphine therapy in postoperative infants the number of neonates and children was small compared with that of adults (49, 90 and 1073, respectively), the M3G/ M6G ratio remained constant in all subgroups (including neonates, children and adults, patients with renal impairment, and different routes of administration).
In the present study, neonates differed signi®cantly from the older children in median M6G/M ratio (P=0.003) but there were no signi®cant differences between the three older age groups. The M6G/M3G ratio at 24 h after i.v. morphine was not signi®cantly different between the four age groups (0±3 yr).
Although the data are dif®cult to compare (median vs mean weighted values 7 ), both studies result in similar conclusions: (i) neonates differ signi®cantly from older patients (children and adults, respectively), having an immature morphine metabolism; (ii) children older than 4 weeks metabolize morphine like older children, as presented in our study, and like adults; 7 and (iii) the M6G/M3G ratio remains constant at all ages.
Hartley and colleagues 37 reported decreasing M6G/M3G plasma ratios, although not signi®cantly, with increasing birth weight. This might suggest a differential development of enzymes (UGT2B7) for the formation of M3G and M6G. Recently, it was shown that UGT2B7 is responsible for the glucuronidation of morphine and is capable of catalysing the glucuronidation of both the 3-and 6-hydroxyl moieties on these molecules. 40 41 However, polymorphism in the coding sequence, as well as in the 5¢-¯anking region, may affect the rate of morphine glucuronidation and can result in individual differences. 42 The SSS was developed as a measure of the severity of surgical stress. 18 Although in the present study the scores did not differ signi®cantly between age or treatment groups, multiple regression analysis showed that they signi®cantly in¯uenced the dosage of morphine required. In the absence of other methods that can directly measure postoperative pain across different age groups, the SSS may help to assess the need for postoperative morphine.
Eight of the 11 children who showed respiratory insuf®ciency were in the IM treatment group. In most of these patients respiratory depression could not be attributed to the morphine therapy but had to be considered as a complication of their surgical operation.
In conclusion, age is the most important factor in morphine requirement and morphine metabolism. In our previous study investigating the effect of CM and IM on surgical stress responses in the same patient population, infants aged 1±3 yr in the IM group showed greater stress than those in the CM group. 17 Combining the results of both studies, we conclude that morphine given intermittently does not provide any clinical advantages and that a continuous morphine infusion is probably safer in neonates and more effective in older infants. By stratifying for age and carefully monitoring the children's behaviour, we were able to give more precise dosages for postoperative morphine after major non-cardiac surgery. We agree with the recommended dosage for continuous morphine infusions of 7 mg kg ±1 h ±1 in full-term neonates. 27 However, we would advise starting with an infusion rate of 10 mg kg ±1 h ±1 in infants >4 weeks of age. Differences in developmental maturation between neonates and infants indicate the need for individual drug dosages. Increase of the infusion rates should only be based on pain scoring by trained nurses, in order to prevent overdosing.
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